40
Participants
Start Date
February 22, 2021
Primary Completion Date
April 22, 2026
Study Completion Date
April 22, 2026
Teclistamab
Teclistamab will be administered subcutaneously.
Kameda Medical Center, Chiba
Ogaki Municipal Hospital, Gifu
National Hospital Organization Mito Medical Center, Higashiibaraki-gun
Kobe City Medical Center General Hospital, Kobe
National Hospital Organization Kumamoto Medical Center, Kumamoto
Kurume University Hospital, Kurume
Kyoto Kuramaguchi Medical Center, Kyoto
National Hospital Organization Matsumoto Medical Center, Matsumoto
Nagoya City University Hospital, Nagoya
Niigata Cancer Center Hospital, Niigata
National Hospital Organization Okayama Medical Center, Okayama
Osaka International Cancer Institute, Osaka
Japanese Red Cross Osaka Hospital, Osaka
National Hospital Organization Hiroshima-Nishi Medical Center, Ōtake
Japanese Red Cross Medical Center, Shibuya City
Lead Sponsor
Janssen Pharmaceutical K.K.
INDUSTRY